(PharmaNewsWire.Com, December 18, 2021 ) The Research Report on “Womens Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) – Global forecast to 2024″, is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period.
Market Size Estimation:
Both top-down and bottom-up approaches were used to estimate and validate the total size of the women’s healthcare market. These methods were also used extensively to determine the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The revenue generated from the sales of respective products from the respective geographies in the market by leading players were aggregated to get the market value for individual products at the global level. The global market values obtained for each product were added together to get the total global market value for the market.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Prolia is the largest and fastest-growing segment of the market.
Based on drug, the women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. Prolia has shown a considerable year-on-year growth primarily due to increasing unit demand. Prolia has witnessed positive market growth owing to the increasing prevalence of postmenopausal osteoporosis in the US.
The postmenopausal osteoporosis segment is expected to grow at the highest CAGR during the forecast period.
On the basis of application, the women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment is expected to grow at a higher CAGR during the forecast period. The growing prevalence of postmenopausal osteoporosis and a high risk of osteoporosis fractures are the prime factors that contribute towards the large share of this segment. Furthermore, the focus of pharmaceutical players on providing effective drugs for postmenopausal osteoporosis also supports the growth of this segment. The postmenopausal osteoporosis segment also holds the largest share of the market owing to these factors.
The Women’s Health Care Market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), and Apothecus Pharmaceutical (US).
Amgen (US): Amgen (US) is one of the leading providers of the women’s healthcare market. The company’s sales and marketing activities are greatly focused on the US and Europe. The company provides Prolia and Xgeva for the treatment of osteoporosis in postmenopausal women. These drugs have shown a year-on-year double-digit value gain as well as volume growth, and constitute the largest share of the market. Amgen’s EVENITY, meant for the treatment of osteoporosis in postmenopausal women, is also in phase 3 of development. It is being developed in collaboration with UCB (Belgium). The company’s high brand recognition and focus on product innovation have helped it to maintain its foothold in the market.
Geographical Analysis in Detailed:
The global women’s healthcare market is segmented into five major regions, namely, North America, Europe, APAC, Latin America, and the Middle East & Africa. In 2018, North America (US and Canada) was the largest and the fastest-growing regional market for women’s healthcare. The major factors supporting market growth include the growing prevalence of PCOS and postmenopausal osteoporosis, increasing median age of first-time pregnancies, and increased healthcare spending in the US and Canada. Also, the high awareness and understanding regarding contraceptives among American women and the easy access to modern contraception as compared to developing countries propel the market growth in this region.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
